MX2020000246A - Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas. - Google Patents

Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas.

Info

Publication number
MX2020000246A
MX2020000246A MX2020000246A MX2020000246A MX2020000246A MX 2020000246 A MX2020000246 A MX 2020000246A MX 2020000246 A MX2020000246 A MX 2020000246A MX 2020000246 A MX2020000246 A MX 2020000246A MX 2020000246 A MX2020000246 A MX 2020000246A
Authority
MX
Mexico
Prior art keywords
recombinant viral
tropism
human cells
genetic material
viral particles
Prior art date
Application number
MX2020000246A
Other languages
English (en)
Inventor
Andrew J Murphy
Aris N Economides
Christos Kyratsous
Christopher Schoenherr
Leah Sabin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020000246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020000246A publication Critical patent/MX2020000246A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan composiciones y métodos para reorientar partículas de cápsidas virales recombinantes a través de un par de unión proteína:proteína específico que forma un enlace covalente, por ejemplo, isopeptídico, para mostrar un ligando de orientación sobre la proteína de cápsida, en donde el ligando de orientación se une específicamente a un marcador de superficie celular expresado en la célula de interés.
MX2020000246A 2017-06-27 2018-06-27 Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas. MX2020000246A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762525708P 2017-06-27 2017-06-27
PCT/US2018/039878 WO2019006046A2 (en) 2017-06-27 2018-06-27 RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS

Publications (1)

Publication Number Publication Date
MX2020000246A true MX2020000246A (es) 2020-08-10

Family

ID=63080488

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000246A MX2020000246A (es) 2017-06-27 2018-06-27 Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas.
MX2023009051A MX2023009051A (es) 2017-06-27 2020-01-08 Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009051A MX2023009051A (es) 2017-06-27 2020-01-08 Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas.

Country Status (28)

Country Link
US (1) US20200140492A1 (es)
EP (2) EP4219529A1 (es)
JP (3) JP2020525020A (es)
KR (1) KR20200021987A (es)
CN (2) CN110997699A (es)
AU (2) AU2018290885B2 (es)
BR (1) BR112019027866A2 (es)
CA (1) CA3066950A1 (es)
CL (2) CL2019003843A1 (es)
CO (1) CO2019014684A2 (es)
CY (1) CY1126149T1 (es)
DK (1) DK3645553T3 (es)
ES (1) ES2943020T3 (es)
FI (1) FI3645553T3 (es)
HR (1) HRP20230538T1 (es)
HU (1) HUE061908T2 (es)
IL (1) IL271570A (es)
LT (1) LT3645553T (es)
MA (1) MA49514B1 (es)
MD (1) MD3645553T2 (es)
MX (2) MX2020000246A (es)
PH (1) PH12019550269A1 (es)
PL (1) PL3645553T3 (es)
PT (1) PT3645553T (es)
RS (1) RS64233B1 (es)
SG (1) SG11201911614XA (es)
SI (1) SI3645553T1 (es)
WO (1) WO2019006046A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
CA3092451A1 (en) * 2018-02-28 2019-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A modular system for gene and protein delivery based on aav
EP3774926A1 (en) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Display systems for proteins of interest
US11674164B2 (en) 2019-03-18 2023-06-13 Bio-Rad Abd Serotec Gmbh Periplasmic fusion proteins
PE20212357A1 (es) 2019-05-24 2021-12-17 Regeneron Pharma Particulas virales modificadas y usos de estas
EP3983117A4 (en) * 2019-06-11 2023-06-21 Chevron U.S.A. Inc. NATURAL GAS CONTAMINANT REMOVAL MEMBRANES AND METHODS OF USE THEREOF
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
EP4055034A4 (en) * 2019-11-08 2024-05-29 Harvard College VIRAL CAPSID POLYPEPTIDES
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
CN114632148A (zh) * 2020-12-15 2022-06-17 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
WO2023081850A1 (en) 2021-11-04 2023-05-11 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to skeletal muscle
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术(上海)股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024107452A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and determining protein structures and stability in fluids, including biological fluids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
RU2603102C2 (ru) 2009-12-10 2016-11-20 Ридженерон Фармасьютикалз, Инк. Мыши, которые производят антитела, имеющие только тяжелые цепи
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
KR20230158661A (ko) 2014-03-21 2023-11-21 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
US20160018835A1 (en) 2014-07-18 2016-01-21 Retroficiency, Inc. System and method for virtual energy assessment of facilities
WO2016112921A1 (en) * 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
US20180298098A1 (en) 2015-02-26 2018-10-18 Var2 Pharmaceutical Aps Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
EP3141600A1 (en) 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
WO2018035503A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
CA3092451A1 (en) * 2018-02-28 2019-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A modular system for gene and protein delivery based on aav

Also Published As

Publication number Publication date
KR20200021987A (ko) 2020-03-02
JP2024071769A (ja) 2024-05-24
MX2023009051A (es) 2023-08-10
CO2019014684A2 (es) 2020-01-17
RU2020101596A3 (es) 2022-03-22
MD3645553T2 (ro) 2023-07-31
PL3645553T3 (pl) 2023-07-17
CA3066950A1 (en) 2019-01-03
EP3645553A2 (en) 2020-05-06
SI3645553T1 (sl) 2023-06-30
RU2020101596A (ru) 2021-07-27
MA49514A (fr) 2020-05-06
RS64233B1 (sr) 2023-06-30
JP2022186991A (ja) 2022-12-15
AU2023204611A1 (en) 2023-08-03
WO2019006046A3 (en) 2019-02-14
HUE061908T2 (hu) 2023-09-28
LT3645553T (lt) 2023-04-25
WO2019006046A2 (en) 2019-01-03
EP4219529A1 (en) 2023-08-02
PT3645553T (pt) 2023-05-08
CL2020003438A1 (es) 2021-07-23
JP2020525020A (ja) 2020-08-27
MA49514B1 (fr) 2023-06-28
DK3645553T3 (da) 2023-05-22
ES2943020T3 (es) 2023-06-08
CN110997699A (zh) 2020-04-10
FI3645553T3 (fi) 2023-05-22
PH12019550269A1 (en) 2021-01-11
EP3645553B1 (en) 2023-03-15
IL271570A (en) 2020-02-27
AU2018290885B2 (en) 2023-07-27
CY1126149T1 (el) 2023-11-15
CL2019003843A1 (es) 2020-07-24
US20200140492A1 (en) 2020-05-07
AU2018290885A1 (en) 2020-01-16
BR112019027866A2 (pt) 2020-07-07
HRP20230538T1 (hr) 2023-08-04
SG11201911614XA (en) 2020-01-30
CN116891534A (zh) 2023-10-17

Similar Documents

Publication Publication Date Title
MX2023009051A (es) Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas.
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2015012808A (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
PH12019550266A1 (en) Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
MX2019005272A (es) Peptidos cancerigenos universales derivados de telomerasa.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2018009389A (es) Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.
EP4219729A3 (en) Compositions and methods for efficient targeting of transgenes
IN2014DN11272A (es)
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
NZ731491A (en) Cd83 binding proteins and uses thereof
FR3016888B1 (fr) Synthetases de la colistine et cluster de genes correspondants
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
MX2016003302A (es) Metodo de transfeccion de la version soluble pro-apoptotica de la proteina especifica del arresto celular 1 (tgas1) en celulas de glioma mediante nanoparticulas de poliplex-neurotensina.
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها